menu
    • menu
    [{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"GHR-LRX","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"}]

    Find Endocrinology Clinical Drug Pipeline Developments & Deals by Ionis Pharmaceuticals

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ionis Pharmaceuticals

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Ionis Pharmaceuticals

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GHR-LRX

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acrome...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            August 21, 2020

                            Lead Product(s) : GHR-LRX

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ionis Pharmaceuticals

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Ionis Pharmaceuticals

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cimdelirsen

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting S...

                            Details : Undisclosed

                            Product Name : IONIS-GHR-LRx

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            May 30, 2019

                            Lead Product(s) : Cimdelirsen

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ionis Pharmaceuticals

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Ionis Pharmaceuticals

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cimdelirsen

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-ac...

                            Details : Undisclosed

                            Product Name : IONIS-GHR-LRx

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            June 07, 2018

                            Lead Product(s) : Cimdelirsen

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Akcea Therapeutics

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Akcea Therapeutics

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Warfarin Sodium

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Warfarin

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 08, 2018

                            Lead Product(s) : Warfarin Sodium

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Akcea Therapeutics

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Akcea Therapeutics

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clopidogrel

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Clopidogrel

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 05, 2018

                            Lead Product(s) : Clopidogrel

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ionis Pharmaceuticals

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Ionis Pharmaceuticals

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ISIS 681257

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Recipient : Akcea Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascula...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            March 06, 2017

                            Lead Product(s) : ISIS 681257

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Recipient : Akcea Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Ionis Pharmaceuticals

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Ionis Pharmaceuticals

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ISIS-GCGRRx

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Content in Type 2 Diabetes

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            July 06, 2016

                            Lead Product(s) : ISIS-GCGRRx

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Ionis Pharmaceuticals

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Ionis Pharmaceuticals

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ISIS-GCGRRx

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 Diabetes

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            October 22, 2015

                            Lead Product(s) : ISIS-GCGRRx

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Akcea Therapeutics

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Akcea Therapeutics

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pelacarsen

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Recipient : Ionis Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With El...

                            Details : Undisclosed

                            Product Name : IONIS-APO(a)-LRx

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            April 13, 2015

                            Lead Product(s) : Pelacarsen

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Recipient : Ionis Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Ionis Pharmaceuticals

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Ionis Pharmaceuticals

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ISIS-494372

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx in Participants With High Lipopr...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 11, 2014

                            Lead Product(s) : ISIS-494372

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth